StreetInsider.com News Articles

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ: NTHI), Ernexa Therapeutics (NASDAQ: ERNA), and VivoSim Labs (NASDAQ: VIVS) highlight three distinct pathways to potential value creation.

NeOnc Technologies

NeOnc Technologies (NASDAQ: NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Three Biotechs Deliver Catalysts to Watch

Wed, 15 Jul 2026 10:42:42 -0400

NeOnc Technologies

Form 8-K NEONC TECHNOLOGIES HOLDI For: Jul 15

Wed, 15 Jul 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260715/26772015.html

Form 8-K NEONC TECHNOLOGIES HOLDI For: Jul 15

Wed, 15 Jul 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260715/26772015.html

NeOnc gets FDA manufacturing feedback for NEO212 tablet transition

Wed, 15 Jul 2026 09:02:24 -0400

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) announced it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing and controls development program for NEO212, its temozolomide-perillyl alcohol conjugate for central nervous system cancers.

The written feedback was provided ahead of a Type B End-of-Phase 1 meeting originally scheduled for July 9, 2026. After reviewing the FDA's responses, NeOnc determined a meeting was not required and canceled it. Under FDA practice, the written responses constitute the official record of the meeting.

Key points in the FDA's feedback include a determination that NeOnc's proposed CMC development approach appears reasonable,

NeOnc gets FDA manufacturing feedback for NEO212 tablet transition

Wed, 15 Jul 2026 09:02:24 -0400

Key points in the FDA's feedback include a determination that NeOnc's proposed CMC development approach appears reasonable,

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

Wed, 15 Jul 2026 09:00:00 -0400

FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212

CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company’s novel temozolomide-perillyl alcohol conjugate.

The written feedback was provided in advance of a Type B End-of-Phase 1 meeting scheduled for